Designed to Fail: Why Regulatory Agencies Don’t Work

William Sanjour*

Albert Einstein said the definition of insanity is doing the same thing over and over again and expecting different results. We have been “reforming” regulatory agencies over and over again, and over and over again they have failed. Yet, as a result of the recent catastrophic failures of regulatory agencies, politicians and pundits are talking about the same old “Regulatory Reform” again.  “Fill the regulatory agencies with honest people who won’t cave in to special interests.”  “Give them more money, more authority and more people.”  But my experience has shown that by concentrating all legislative, executive and judiciary authority in one regulatory agency just makes it easier for it to be corrupted by the industries it regulates.

I worked for the US Environmental Protection agency for 30 years and lived through many cycles of “Regulatory Reform,” doing the same “reforms” over and over again and expecting different results. I’ve learned that the way to achieve true regulatory reform is to give regulatory agencies less money, less authority, fewer people but more intelligent regulations. The theme of this article is that by dispersing regulatory authority, rather than concentrating it, we would make corruption more difficult and facilitate more sensible regulation.
… Continue Reading

‘Phantom Heritability’ Indicates Poor Predictive Value of Gene Tests

Helen Wallace, GeneWatch UK (photo credit: jurvetson)

Last week, a paper on “phantom heritability” was published by a research group led by Eric Lander, one of the leading contributors to understanding the implications of the Human Genome Project (HGP) for common, complex diseases such as heart disease and cancer (1). The paper has created excitement amongst scientists who have been critical of the claims made for the likely impacts of the HGP on health and medicine. This is not because the paper makes a startling new discovery, but because it is an important step towards recognition of these long standing criticisms. … Continue Reading

Psychiatrists plead to continue funding of genetic approaches to disease

Jonathan Latham

Ninety six leading psychiatric geneticists have publicly requested their scientific funding agencies not to abandon the search for genetic links to mental health. In a letter, published Aug 9th in the journal Molecular Psychiatry, they argue that the ongoing failure to uncover significant disease genes for mental illness does not indicate that current research is fundamentally misdirected.

Instead, they believe that current experimental designs lack sufficient statistical power. And it is a defect they want remedied by further studies. “Since family history is a major risk factor” they write “we urge the major funding bodies worldwide to continue to support GWAS (Genome-Wide Association Studies) as a major investigative tool’. … Continue Reading

23andMe disproves its own business model

Jonathan Latham

Online gene testing company 23andMe last week published its first genetic research study into Parkinson’s Disease. The study was funded by the participants (many of whom are customers of 23andMe), the company itself, and Google-founder Sergei Brin, who is married to 23andMe’s CEO and founder, Anne Wojcicki (1). Wojcicki is also personally subsidising the company and is a co-author on the paper.

23andMe’s study shows that two new genes it has discovered, plus all known existing genes linked to the disease, are not much better than random selection for predicting who will get Parkinson’s Disease. … Continue Reading

The Great DNA Data Deficit: Are Genes for Disease a Mirage?

Jonathan Latham and Allison Wilson

Just before his appointment as head of the US National Institutes of Health (NIH), Francis Collins, the most prominent medical geneticist of our time, had his own genome scanned for disease susceptibility genes. He had decided, so he said, that the technology of personalised genomics was finally mature enough to yield meaningful results. Indeed, the outcome of his scan inspired The Language of Life, his recent book which urges every individual to do the same and secure their place on the personalised genomics bandwagon.

… Continue Reading

Strangely like Fiction: Sponsored Academics Admit Falsely Claiming Dairy Hormone Safety Endorsements

Jonathan Latham and Allison Wilson

The fight over rbGH (recombinant bovine growth hormone) continues, even under new ownership.

After acquiring rbGH from Monsanto, Elanco (part of Eli Lilly) has stepped up efforts to convince milk processors and the wider food industry that milk from rbGH-injected cows is safe. Central to their new campaign is a paper, commissioned through PR company Porter-Novelli, from eight prominent experts and academics in medicine and dairy science (Recombinant bovine somatotropin (rbST): a safety assessment).
… Continue Reading